PMID- 31719808
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1551-6776 (Print)
IS  - 2331-348X (Electronic)
IS  - 1551-6776 (Linking)
VI  - 24
IP  - 6
DP  - 2019 Nov-Dec
TI  - Survey of Pharmacists Regarding the Use of Propofol Infusions in the PICUs in 
      North America.
PG  - 473-478
LID - 10.5863/1551-6776-24.6.473 [doi]
AB  - OBJECTIVE: The objective of this survey was to assess the current use of 
      continuous infusion propofol in PICUs across the United States and Canada. 
      METHODS: A list of institutions with PICU beds/units was identified through the 
      residency directories available on the American Society of Health-Systems 
      Pharmacists (ASHP) and Canadian Society of Hospital Pharmacists (CHSP) Web sites. 
      A REDCap questionnaire was sent to each identified institution's program director 
      via email. An initial reminder email was sent out 2 weeks later and a second 
      reminder email was sent 4 weeks after the initial request. The survey was closed 
      at 6 weeks. RESULTS: A total of 514 emails were sent to residency program 
      directors, and 50 pharmacists responded to the survey. Of the pharmacists that 
      did respond, 27 (54%) reported using propofol while 23 (46%) did not. Of those 
      that did not, 43.5% reported the FDA boxed warning as the primary reason. 
      Thirty-seven percent of respondents using propofol felt comfortable using a 
      maximum infusion rate of 200 mcg/kg/min. Twenty-nine percent, 25%, and 33% of 
      those who responded as using propofol felt comfortable using this agent for a 
      maximum duration of 24, 48, and 72 hours, respectively. The majority of 
      respondents using propofol did not have a case of propofol-related infusion 
      syndrome. CONCLUSIONS: Despite the FDA warning, propofol is used as a continuous 
      infusion (with variable limitations) by a majority of pharmacists in North 
      America. Self-reported incidence of propofol-related infusion syndrome (PRIS) 
      remains low.
CI  - Copyright Published by the Pediatric Pharmacy Association. All rights reserved. 
      For permissions, email: mhelms@pediatricpharmacy.org 2019.
FAU - Kurek, Kenneth J
AU  - Kurek KJ
FAU - Harthan, Aaron A
AU  - Harthan AA
FAU - Tripathi, Sandeep
AU  - Tripathi S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Pediatr Pharmacol Ther
JT  - The journal of pediatric pharmacology and therapeutics : JPPT : the official 
      journal of PPAG
JID - 101089851
PMC - PMC6836699
OTO - NOTNLM
OT  - adverse drug effect
OT  - continuous infusion
OT  - pediatrics
OT  - propofol
OT  - propofol-related infusion syndrome
COIS- Disclosure The authors declare no conflicts or financial interest in any product 
      or service mentioned in the manuscript, including grants, equipment, medications, 
      employment, gifts, and honoraria.
EDAT- 2019/11/14 06:00
MHDA- 2019/11/14 06:01
PMCR- 2019/11/01
CRDT- 2019/11/14 06:00
PHST- 2019/11/14 06:00 [entrez]
PHST- 2019/11/14 06:00 [pubmed]
PHST- 2019/11/14 06:01 [medline]
PHST- 2019/11/01 00:00 [pmc-release]
AID - 10.5863/1551-6776-24.6.473 [doi]
PST - ppublish
SO  - J Pediatr Pharmacol Ther. 2019 Nov-Dec;24(6):473-478. doi: 
      10.5863/1551-6776-24.6.473.